Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 25 Sept 2026 for Definium Therapeutics, Inc., €100k.
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Matthew Thomas Wiley: trading record in brief
All filings by Matthew Thomas Wiley on record concern Definium Therapeutics, Inc. Between 25 June 2026 and 25 September 2026, the trades on record add up to 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The newest entry dates from 25 September 2026: a transaction of €100k, in Definium Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Matthew Thomas Wiley
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
3,097 shares@ US$36.73CommonSEC144:0001950047-26-009816
2,867 shares@ US$42.13100.0% of flowCommonSEC144:0001950047-26-006492
2 of 2 declarations
